Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 60,000 | 0.1288% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.21% | -1.34% | +53.17% | +60.65% | 53.83B | |
| +5.37% | +0.75% | +50.39% | +83.03% | 52.1B | |
| -1.20% | -1.94% | +4.13% | +402.68% | 23.48B | |
| +0.74% | +2.32% | -15.38% | -14.44% | 23.13B | |
| +3.46% | +0.79% | +34.01% | -4.47% | 19.36B | |
| -1.18% | -1.15% | +30.12% | -32.02% | 17.56B | |
| -1.67% | -8.56% | +163.95% | +284.69% | 15.2B | |
| +3.62% | -2.42% | +29.70% | +663.64% | 14.83B | |
| -0.70% | -0.91% | +25.46% | +179.47% | 14.06B | |
| Average | +0.88% | -2.44% | +41.73% | +180.36% | 25.95B | |
| Weighted average by Cap. | +1.48% | -2.34% | +41.56% | +140.24% |
Employees
51
